GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » ANGLE PLC (LSE:AGL) » Definitions » Construction In Progress

ANGLE (LSE:AGL) Construction In Progress : £0.00 Mil (As of Dec. 2023)


View and export this data going back to 2004. Start your Free Trial

What is ANGLE Construction In Progress?


ANGLE Construction In Progress Historical Data

The historical data trend for ANGLE's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ANGLE Construction In Progress Chart

ANGLE Annual Data
Trend Apr14 Apr15 Apr16 Apr17 Apr18 Apr19 Dec20 Dec21 Dec22 Dec23
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

ANGLE Semi-Annual Data
Apr14 Oct14 Apr15 Oct15 Apr16 Oct16 Apr17 Oct17 Apr18 Oct18 Apr19 Oct19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

ANGLE Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.


ANGLE (LSE:AGL) Business Description

Traded in Other Exchanges
Address
10 Nugent Road, The Surrey Research Park, Surrey, Guildford, GBR, GU2 7AF
ANGLE PLC is active in the healthcare sector in the United Kingdom. It is a medical diagnostic company specializing in the development of pioneering products in cancer diagnostics. Its patented Parsortix technology can potentially treat and diagnose various forms of cancer. The Parsortix system can capture and harvest CTCs from patient blood. Its geographical segments include Europe and North America, of which majority of its revenue is generated from Europe.